![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CV THERAPEUTICS INITIATES CLINICAL PROGRAM FOR CVT-6883
CV THERAPEUTICS INITIATES CLINICAL PROGRAM FOR CVT-6883
July 15, 2005
CV Therapeutics has initiated a clinical program for CVT-6883, a selective, potent and orally available A2B-adenosine receptor antagonist intended to treat asthma with a daily dosage. Blocking the A2B-adenosine receptor may limit or prevent mast cell degranulation, which in turn may lead to bronchoconstriction and the inflammatory process associated with asthma and cardiopulmonary disease, the company said.
A randomized, double-blind, placebo-controlled, single dose Phase I study of oral CVT-6883 in 24 healthy adults is currently assessing the safety and tolerability of a range of doses of CVT-6883.
CV Therapeutics has a U.S. patent covering CVT-6883 and other proprietary selective adenosine A2B-receptor antagonists.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct